Regeneron Pharmaceuticals, Inc. gave investors some unexpected potential good news during its second quarter sales and earnings call on 3 August, saying that its US filing of high-dose Eylea may obtain approval during the current quarter, perhaps even before the end of August, following a US Food and Drug Administration complete response letter on 27 June.
Regeneron Raises Possibility Of Quick CRL Resolution For High-Dose Eylea
On its Q2 earnings call, Regeneron said its 8mg formulation of aflibercept could obtain US FDA approval this quarter, despite receiving a complete response letter in June. Refiling’s fate tied to review of pozelimab.
More from Strategy
More from Business
• By
Chinese biopharma companies’ alliance strategies are transitioning from immediate cash needs to more strategic management of portfolios, as MNCs continue to hunt for derisked assets.
• By
As drugmakers update investors on first quarter financial performance, uncertainty around global trade and US regulatory oversight is likely to dominate discussions.
• By
Faced with Trump’s hostile tariff moves, the UK aims to speed up clinical trial start times to support its pharma sector and invest £600m in a new health data research service.